Incyte Releases Mixed Data From Late-Stage Opzelura Studies In Skin Disease Characterized By Itchy Firm Lumps
Incyte Corporation (NASDAQ:INCY) revealed results from its pivotal Phase 3 TRuE-PN clinical trial program –TRuE-PN1 and ...
Medscape6d
Topical Ruxolitinib Improves Itch, Blistering in Prurigo Nodularis in Study
Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...
Healio12d
‘Landmark’ study shows potential of ruxolitinib cream 1.5% for prurigo nodularis
Ruxolitinib cream 1.5% shows “breakthrough” results as a treatment for prurigo nodularis, according to a presenter at the ...
Fierce Pharma13d
Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts
As Incyte strives to push its topical JAK inhibitor Opzelura into additional dermatology indications, the company’s latest ...
Incyte announces results from Phase 3 TRuE-PN trial
Incyte (INCY) announced results from its pivotal Phase 3 TRuE-PN clinical trial program -TRuE-PN1 and TRuE-PN2 studies – evaluating the safety ...
Nasdaq27d
Arcutis Announces Publication Of Positive Data From INTEGUMENT-PED Trial Evaluating ZORYVE
and Worst Itch Numeric Scale (WI-NRS) at Week 4. The data also show improvement in itch (pruritus) was observed as early as 24 hours after first application. "AD is a chronic, inflammatory skin ...